Orphazyme sells entire business to US biotech company

Embattled biotech company Orphazyme has found a buyer in the form of a US-based biotech firm. If and when the deal is completed, the Danish company will close, and the majority of the remaining 20 employees will be transferred to the new owner.

Photo: Nikolaj Skydsgaard/REUTERS / X07081

Orphazyme has found a buyer after months of speculation.

The listed company, which has been going through a restructuring process, announced the planned acquisition in a stock exchange notification.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs